| Multiple Sclerosis |
1 |
1 |
| COVID-19 |
0 |
0.99 |
| Receptors |
0 |
0.52 |
| Otolaryngology |
0 |
0.41 |
| California |
0 |
0.35 |
| Multiple Sclerosis Relapse |
0 |
0.35 |
| Macular Edema |
0 |
0.25 |
| Progressive Multifocal Leukoencephalopathy |
0 |
0.25 |
| Upper Respiratory Tract Infection |
0 |
0.25 |
| Pain Management |
0 |
0.18 |
| Abscess |
0 |
0.17 |
| Colitis |
0 |
0.17 |
| Disability |
0 |
0.17 |
| Disease-Modifying Therapy |
0 |
0.17 |
| Dorsum |
0 |
0.17 |
| Edema |
0 |
0.17 |
| Grant |
0 |
0.17 |
| Interferon Beta |
0 |
0.17 |
| Leukoencephalopathy |
0 |
0.17 |
| Lymphocytes |
0 |
0.17 |
| Match |
0 |
0.17 |
| Nasopharyngitis |
0 |
0.17 |
| Pain |
0 |
0.17 |
| Pandemic |
0 |
0.17 |
| Respiratory Tract |
0 |
0.17 |
| Back Pain |
0 |
0.15 |
| Ulcerative Colitis |
0 |
0.15 |
| Biologic Therapy |
0 |
0.11 |
| Headache |
0 |
0.11 |
| Hypertension |
0 |
0.11 |
| Inflammatory Bowel Disease |
0 |
0.11 |
| Medical Life |
0 |
0.11 |
| Retinal Diseases |
0 |
0.11 |
| Toxicology |
0 |
0.11 |